This episode of SciShow is supported by Brilliant.
Go to Brilliant.org/SciShow to check out their Knowledge and Uncertainty course.
[♪ INTRO]
This video was filmed on September 1st, 2020.
For the most up to date information we have on the COVID-19 pandemic,
please refer to the playlist linked in the description.
On August 11th, Vladimir Putin announced Russian health agencies had approved
the world’s first vaccine for widespread use against COVID-19: Sputnik V.
Yes, that’s really what they decided to call it.
And it’s potentially really good news!
But, many experts are skeptical as to whether the vaccine actually works,
because it’s been tested in a really weird way.
Vaccines are technically drugs, and get approved by regulatory drug agencies.
They’re supposed to publicly prove themselves in a very specific set of scientific tests.
This is, in large part, why vaccines as a whole are so safe and effective.
But this is not what happened with this Russian vaccine.
Its developers haven’t published any of the results from human tests.
And they claimed success even before starting
the kind of testing you need to see if a vaccine actually works.
Alright, so, to back up: drug trials in humans, also known as clinical trials,
are typically organized into four to five stages, or phases.
These can sometimes be combined, but they’re usually discrete,
because each builds on the previous ones.
In the US, they are creatively named Phases 0, I, II, III, and IV.
But Phase IV actually happens after the drug hits the market,
so we’re going to focus on Phases 0 through III here.
Phases 0 and I are generally short, small studies intended to establish that
the drug does the very basics of what it’s supposed to do,
and doesn’t cause tons of harm in the process.
Since these trials are usually the first time a drug has been given to people,
researchers are really watching out for negative side effects, or, in trial lingo: adverse events.
They also generally try to figure out what dose would be best.
For instance, a Chinese company called CanSino
began a Phase I trial for their COVID-19 vaccine on March 16th.
They gave 108 participants a low, medium, or high dose of the vaccine.
And while quite a few of those people had mild to moderate side effects
like fatigue and headaches, the vaccine appeared safe enough to use in people.
So, it moved to Phase II.
Here, scientists continue to look for adverse events and evaluate dosing.
And the question of whether the drug actually does anything becomes more prominent.
Participant numbers also typically go up.
Like, CanSino’s Phase II tested two different doses against a placebo in about 500 people.
And, as hoped, vaccinated participants started producing antibodies
that can neutralize the virus, and had other promising immune responses as well.
Now, at this point, you might be wondering
how Sputnik V fared in its Phase I and II trials. And so is everyone.
Although two combined Phase I and II trials for it
are listed online as “complete”, their results haven’t been published.
So, everything we know comes from the Russian government and the researchers involved.
There’s no public data about how the vaccine works, or how well those trials went.
But more to the point: even if they did go well,
positive Phase II results don't guarantee the vaccine works in the real world.
While things like antibody levels are associated with protection in animals,
immune reactions are complicated.
And Phase II trials don’t actually test whether a vaccine prevents people from getting sick.
That doesn’t happen until Phase III.
These trials are typically hundreds, thousands,
or even tens of thousands of participants larger.
That’s in part because researchers want to see
if or how many people catch the disease after getting the vaccine.
So, they need lots of people, to make sure that a good number of them
are exposed to the virus in their daily lives.
And that can take a long time,
which is why Phase III trials usually take a year or years, start to finish.
Another reason for the big numbers at this phase is to spot rare and serious adverse events.
Even something that happens once in every ten thousand vaccinations
can be a big deal, since we may want to vaccinate hundreds of millions of people.
And these also can take some time to manifest.
So Phase III trials are really important, both as measures of how well a vaccine works
and how safe it really is, and their large numbers and longer time tables are key to all of that.
Now... when Putin made the announcement,
it wasn’t clear if Russia was planning to start one of these trials.
Since then, other sources have said that the vaccine’s approval is actually dependent on
positive Phase III results, and that those trials have started,
or will start soon?… in several countries; the details are still fuzzy.
Even if that’s the case, though, government officials have also said that
they want to start administering this vaccine in October,
which wouldn’t give those trials time to show anything.
That’s why doctors and public health experts are so unnerved by how this is all playing out.
Now, Russia isn’t the only one taking risks or skipping steps
in the hopes of delivering a vaccine as soon as possible.
Like, here in the US, a company called Moderna launched into Phase I and II trials
for their COVID-19 vaccine before completing pre-clinical trials in animals.
Then, they went into Phase III before finishing Phase II
or publishing the full results from Phase I.
Also, the pharmaceutical company Pfizer announced that
they may apply for FDA approval for their vaccine candidate in October,
even though it'll still be in Phase II and III trials.
And while it would be unprecedented for the FDA to grant them that approval,
this week, the FDA commissioner said the agency might consider
an emergency use authorization, if a company
submitted compelling paperwork before the end of clinical trials.
Which in another way, isn’t that unusual;
we have emergency authorizations for other COVID-19 therapeutics in America.
And China has implemented their own version of
emergency vaccine authorization for their military and at-risk citizens,
even though their vaccines are still in clinical trials.
But that’s not what Russia initially said they were doing,
and it’s still not entirely clear what’s going on.
They seem to be all in on this as yet unproven vaccine.
And that’s a pretty risky bet, considering that more than a third of drugs
that do well in Phases I and II fail in Phase III.
It’s possible, of course, that the gamble will pay off.
Sputnik V could be a safe and effective vaccine.
But, if the vaccine doesn’t work, or worse, proves truly harmful,
it could hurt a lot of people, undermine control efforts,
and ruin everyone’s trust in whatever vaccine or vaccines succeed it.
It would be amazing if this vaccine pans out.
But over the years, we’ve developed a very specific and rigorous method
to make sure any drug or vaccine is as effective and safe as possible.
And this one isn’t following it.
So, at this point, all we can do is wait and see.
All this uncertainty surrounding, like, everything to do with this pandemic is hard.
Uncertainty is hard in general.
But you can become better at dealing with everything you don’t know,
with a little help from today’s sponsor, Brilliant.
Their Knowledge and Uncertainty course dives deep
into the math behind uncertainty so you can feel more confident
in the conclusions you draw from the flood of conflicting information.
And they have more than 60 other courses covering topics in science, engineering,
math, and computer science, so you can level up your other STEM skills, too.
And if you’re one of the first 200 people to sign up at Brilliant.org/SciShow,
you’ll get 20% off an annual Premium subscription.
So, check it out if you’re interested. And thanks for watching SciShow!
[♪ OUTRO]